Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tiagabine.

S C Schachter1

  • 1Harvard Medical School, Boston, Massachusetts, USA.

Drugs of Today (Barcelona, Spain : 1998)
|April 20, 2004
PubMed
Summary
This summary is machine-generated.

Tiagabine, an antiepileptic drug, uniquely inhibits gamma-aminobutyric acid uptake. It is effective for partial seizures with a favorable safety profile, offering a new treatment option for epilepsy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Huperzine A prophylaxis against pentylenetetrazole-induced seizures in rats is associated with increased cortical inhibition.

Epilepsy research·2015
Same author

Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor protein 695.

Neuroscience·2007
Same author

Oxcarbazepine: current status and clinical applications.

Expert opinion on investigational drugs·2005
Same author

Vagus nerve stimulation: current status and clinical applications.

Expert opinion on investigational drugs·2005
Same author

Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

Neurology·2004
Same author

Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

Neurology·2004
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Area of Science:

  • Pharmacology
  • Neurology
  • Epilepsy Treatment

Background:

  • Tiagabine is an antiepileptic drug (AED) with a unique mechanism of action.
  • It specifically inhibits the reuptake of gamma-aminobutyric acid (GABA) into neurons and glia.
  • This distinguishes it from other available AEDs.

Purpose of the Study:

  • To evaluate the efficacy and safety of tiagabine as an antiepileptic treatment.
  • To assess its pharmacokinetic profile and potential drug interactions.
  • To determine its utility in managing medically refractory epilepsy.

Main Methods:

  • Efficacy was assessed in animal seizure models.
  • Safety evaluations included teratogenicity, carcinogenicity, and mutagenicity studies in animals.

Related Experiment Videos

  • Pharmacokinetic studies examined drug metabolism, interactions with other AEDs and non-AEDs, and effects of age.
  • Clinical trials evaluated tiagabine as add-on therapy for partial seizures.

    • Main Results:

    • Tiagabine demonstrated efficacy in animal seizure models at subtoxic doses.
    • No evidence of clinically significant teratogenicity, carcinogenicity, or mutagenicity was found in animals.
    • Tiagabine showed no clinically relevant effects on hepatic metabolism or serum levels of other AEDs.
    • Adverse effects were generally mild to moderate, with dizziness, asthenia, and somnolence being most common.
    • Tiagabine was effective as add-on therapy for partial seizures in doses of 32-56 mg daily.
    • It is effective when dosed 2-3 times daily, despite a short half-life in patients on enzyme-inducing AEDs.

    Conclusions:

    • Tiagabine is an effective add-on therapy for partial seizures in medically refractory epilepsy.
    • It possesses a unique mechanism of action and a favorable safety profile.
    • Its predictable pharmacokinetics and limited drug interactions enhance its therapeutic value.
    • Tiagabine expands treatment options for patients with epilepsy.